Loader

Pathways

PathWhiz ID Pathway Meta Data

PW000112

Pw000112 View Pathway
disease

Saccharopinuria/Hyperlysinemia II

Homo sapiens
Saccharopinuria (also known as: saccharopinemia, saccharopine dehydrogenase deficiency, and alpha-aminoadipic semialdehyde synthase deficiency) is caused by a partial deficiency of aminoadipic semialdehyde synthase (AASS) enzyme and causes an increase in saccharopine in the urine. Saccharopinuria is another form of hyperlysinemia. AASS has lysine ketoglutarate reductase (LKR) and saccharopine dehydrogenase (SDH) activity. AASS acts in the first 2 steps in lysine degradation. A defect in this enzyme results in accumulation of citrulline, lysine and saccharopin in the plasma; lysine in the spinal fluid; and citrulline, lysine and saccharopine in the urine. Symptoms include growth and mental retardation.

PW127265

Pw127265 View Pathway
disease

Saccharopinuria/Hyperlysinemia II

Homo sapiens
Saccharopinuria (also known as: saccharopinemia, saccharopine dehydrogenase deficiency, and alpha-aminoadipic semialdehyde synthase deficiency) is caused by a partial deficiency of aminoadipic semialdehyde synthase (AASS) enzyme and causes an increase in saccharopine in the urine. Saccharopinuria is another form of hyperlysinemia. AASS has lysine ketoglutarate reductase (LKR) and saccharopine dehydrogenase (SDH) activity. AASS acts in the first 2 steps in lysine degradation. A defect in this enzyme results in accumulation of citrulline, lysine and saccharopin in the plasma; lysine in the spinal fluid; and citrulline, lysine and saccharopine in the urine. Symptoms include growth and mental retardation.

PW122007

Pw122007 View Pathway
disease

Saccharopinuria/Hyperlysinemia II

Rattus norvegicus
Saccharopinuria (also known as: saccharopinemia, saccharopine dehydrogenase deficiency, and alpha-aminoadipic semialdehyde synthase deficiency) is caused by a partial deficiency of aminoadipic semialdehyde synthase (AASS) enzyme and causes an increase in saccharopine in the urine. Saccharopinuria is another form of hyperlysinemia. AASS has lysine ketoglutarate reductase (LKR) and saccharopine dehydrogenase (SDH) activity. AASS acts in the first 2 steps in lysine degradation. A defect in this enzyme results in accumulation of citrulline, lysine and saccharopin in the plasma; lysine in the spinal fluid; and citrulline, lysine and saccharopine in the urine. Symptoms include growth and mental retardation.

PW121782

Pw121782 View Pathway
disease

Saccharopinuria/Hyperlysinemia II

Mus musculus
Saccharopinuria (also known as: saccharopinemia, saccharopine dehydrogenase deficiency, and alpha-aminoadipic semialdehyde synthase deficiency) is caused by a partial deficiency of aminoadipic semialdehyde synthase (AASS) enzyme and causes an increase in saccharopine in the urine. Saccharopinuria is another form of hyperlysinemia. AASS has lysine ketoglutarate reductase (LKR) and saccharopine dehydrogenase (SDH) activity. AASS acts in the first 2 steps in lysine degradation. A defect in this enzyme results in accumulation of citrulline, lysine and saccharopin in the plasma; lysine in the spinal fluid; and citrulline, lysine and saccharopine in the urine. Symptoms include growth and mental retardation.

PW146073

Pw146073 View Pathway
drug action

Sacubitril Drug Metabolism Action Pathway

Homo sapiens

PW130361

Pw130361 View Pathway
metabolic

Safflower Drug Metabolism

Homo sapiens

PW128300

Pw128300 View Pathway
drug action

Safinamide Action Pathway

Homo sapiens
Safinamide is a monoamide oxidase inhibitor. It is indicated as an odd treatment of levodopa for Parkinson's disease. The monoamine oxidase is an enzyme that catalyzes the oxidative deamination of many amines like serotonin, norepinephrine, epinephrine, and dopamine. There are 2 isoforms of this protein: A and B. The first one is found in cells located in the periphery and breakdown serotonin, norepinephrine, epinephrine, dopamine, and tyramine. The second one, the B isoform, breakdowns phenylethylamine, norepinephrine, epinephrine, dopamine, and tyramine. This isoform is found in the extracellular tissues and mostly in the brain. The mechanism of action of the MAOIs is still not determined, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. MAO A inhibition is thought to be more relevant to antidepressant activity than the inhibition caused by MAO B. Selective MAO B inhibitors have no antidepressant effects. Safinamide has multiple mechanisms of action and a very high therapeutic index, it binds only the B isoform of MAO but it also inhibits sodium and calcium channels and the glutamate release channels. This drug is administered as an oral tablet. An overdose of this drug will result in uncontrolled movements, falls, nausea, insomnia, hypertension, and hallucinations.

PW145730

Pw145730 View Pathway
drug action

Safinamide Drug Metabolism Action Pathway

Homo sapiens

PW122244

Pw122244 View Pathway
signaling

Saim Momin

Homo sapiens

PW122249

Pw122249 View Pathway
signaling

Saim Momin `1

Homo sapiens